PAVmed Inc. (PAVMZ)

Overview

PAVmed Inc. is a prominent medical device company based in the United States, specializing in the development, manufacture, and sale of innovative medical devices intended to improve patient outcomes across a broad spectrum of healthcare needs. Originally operating under the name PAXmed Inc., the company underwent a rebranding to PAVmed Inc. in April 2015, signaling a reinvigorated commitment to advancing medical care through cutting-edge technology. Since its inception in 2014, PAVmed has been headquartered in New York, New York, positioning itself as a key player in the medical device sector with a focus on minimally invasive treatments, early detection technologies, and next-generation sequencing DNA assays.

Products and Services

• CarpX

  A patented, single-use, disposable surgical device designed for the minimally invasive treatment of carpal tunnel syndrome. CarpX represents a significant advancement in the field of hand and wrist surgery, offering a less invasive alternative to traditional surgical techniques, potentially leading to faster recovery times and reduced complications.

• EsoCheck

  An innovative esophageal cell collection device engineered for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). EsoCheck's non-invasive approach facilitates easy and safe cell sample collection, allowing for early intervention and management of esophageal conditions.

• EsoGuard

  A next-generation sequencing DNA assay that works in conjunction with EsoCheck. Utilizing bisulfite-converted DNA sequencing technology, EsoGuard provides a highly sensitive and specific analysis for the early detection of esophageal dysplasia and cancer, offering a revolutionary approach to esophageal health monitoring.

• EsoCure

  An esophageal ablation device currently in the pipeline, aimed at treating dysplastic Barrett's Esophagus (BE). EsoCure is designed to safely and effectively remove precancerous tissue from the esophagus, thereby preventing the progression to esophageal adenocarcinoma.

• PortIO

  An implantable intraosseous vascular access device that offers a long-term solution for patients requiring frequent or ongoing intravenous treatments. PortIO's innovative design allows for direct access to the bone marrow, providing a reliable and efficient route for the administration of medications, fluids, and nutrients.

• NextFlo

  A work-in-progress fluid management technology that promises to offer precise and adjustable infusion rates without the need for electronic pumps. NextFlo aims to revolutionize the administration of IV fluids and medications by providing a cost-effective, user-friendly solution with potential applications across various healthcare settings.

• Veris

  A cancer care platform still in the development phase, designed to enhance the treatment and monitoring of cancer patients. The Veris platform encapsulates a broad array of services and technologies aimed at improving patient outcomes through personalized medicine, with a focus on accessibility and integration of care.